Home » AETERNA ZENTARIS COMPLETES ENROLLMENT FOR OZARELIX TRIAL
AETERNA ZENTARIS COMPLETES ENROLLMENT FOR OZARELIX TRIAL
AEterna Zentaris has completed enrollment for a Phase II trial with ozarelix in hormone-dependent prostate cancer, ahead of the projected schedule. This multicenter trial is designed to evaluate the effects of ozarelix on hormonal levels, in particular testosterone, as well as objective anti-tumor effects. This open-label trial involving 48 patients is being conducted in Europe in collaboration with its partner Spectrum Pharmaceuticals.
Ozarelix is a fourth generation luteinizing hormone releasing hormone antagonist administered as a depot formulation for the treatment of hormone-dependent prostate cancer.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May